Pharma Focus Asia

Arecor and TRx BioSciences Establish Partnership for Advancing Oral GLP-1 Therapy with Improved Bioavailability

Wednesday, March 13, 2024

Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on advancing modern therapies for improved health outcomes, has teamed up with TRx Biosciences Limited, a leader in innovative lipid technology for oral drug delivery. Together, they have announced a research collaboration aimed at formulating an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.

GLP-1 receptor agonists are crucial for managing type 2 diabetes and obesity. The global market for these treatments is projected to reach $80-$100+ billion by 2030. However, delivering these drugs orally presents significant challenges due to the digestive system's proteolytic nature, resulting in reduced bioavailability. Currently, injection remains the primary delivery method, limiting patient adoption, compliance, and usage.

The only oral GLP-1 receptor agonist available to patients is Novo Nordisk’s semaglutide (Rybelsus®), which boasts less than 1% oral bioavailability. To address this issue, Arecor and TRx Biosciences plan to utilize TRx Biosciences’ LipiCore™ oral delivery technology along with Arecor’s formulation platform, Arestat™. This collaboration aims to develop an oral GLP-1 receptor agonist product with improved physicochemical properties to achieve higher oral bioavailability and stability.

Sarah Howell, CEO of Arecor, highlighted the ongoing challenges in oral delivery for GLP-1 receptor agonists and expressed optimism in leveraging Arecor's Arestat™ technology alongside TRx Biosciences' expertise to develop an enhanced oral product. Dr. Robin Bannister, CEO of TRx Biosciences, emphasized the importance of effective oral peptide delivery and the potential of combining LipiCore™ with Arecor's platform to unlock novel oral uptake channels and protect peptides during gastrointestinal transit.

The collaboration aims to extend beyond the initial GLP-1 receptor agonist program to develop additional oral peptide products, potentially targeting obesity-related health conditions and other therapeutic areas. Success in this endeavor could revolutionize oral peptide therapy, providing patients with more convenient and effective treatment options.

 

Source: globenewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024